Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of BIO-B will - over the next 2 Weeks and hit - by . In that time frame, BIO-B's share price is expected to range between - and -.
BearishAverageBullish| Date | Predicted Lower | Predicted | Predicted Upper | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No Data | |||||||||||||||||||
BIO-B shares fell -0.37% in Monday, April 13, 2026's trading session, dropping from a previous close of $277.00 to move at $275.98. The stock demonstrated notable intraday movement (see BIO-B's key stats for a full breakdown), fluctuating between $275.98 and $275.98, a 0 trading range. While recent weeks have seen some volatility, BIO-B has managed to secure a +3.36% gain over the past 2 weeks. The downward price movement was accompanied by remained steady trading volume, with approximately 3.06 shares changing hands, 0 fewer than the previous session. This amounted to $844.28 in total market activity.
Will BIO-B Continue Its Trend?
According to analyst ratings and projections for BIO-B, Bio-Rad Laboratories, Inc. shares are anticipated to remain stable by -, potentially reaching - per share by January 1, 1970. Short-term technical indicators for BIO-B currently suggest a bearish sentiment. This aligns with the stock's recent performance, as it has recorded 20 negative trading days within the past 30 sessions. Based on the BIO-B stock forecast, now is not the best time to buy BIO-B stock because its current trading price is - our predicted value, hinting at a possible . For deeper insights, view our sentiment analysis on BIO-B covering social and institutional perspectives.
BIO-B Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into BIO-B's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 50.59% to 69.08%) suggest mixed signals, with the stock in a neutral to slightly bearish momentum phase. The 50-day RSI, at 44.86%, suggests a neutral medium-term outlook. Additionally, the 100-day RSI, at 46.85%, maintains a neutral outlook for the long term. Insights into BIO-B's shareholder base show how institutional investors are positioning themselves during these momentum shifts

